Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 2/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3610061 | 0.82 | CYP1A2 (0.56) | CYP1A2CYP2D6MAPTKMT2ARAF1 | |
| SCHEMBL3604836 | 0.79 | PIK3CB (0.57) | CYP1A2CYP2D6MAPTKMT2APIK3CB | |
| SCHEMBL3596067 | 0.78 | KMT2A (0.48) | CYP1A2CYP2D6MAPTKMT2ARAF1 | |
| SCHEMBL3598581 | 0.78 | KMT2A (0.48) | CYP1A2CYP2D6MAPTKMT2ARAF1 | |
| SCHEMBL3599828 | 0.77 | CYP1A2 (0.60) | CYP1A2CYP2D6MAPTKMT2ARAF1 | |
| SCHEMBL13141217 | 0.77 | MAPT (0.60) | CYP1A2CYP2D6MAPTKMT2ARAF1 | |
| SCHEMBL18398994 | 0.77 | CYP1A2 (0.60) | CYP1A2CYP2D6MAPTKMT2ARAF1 | |
| SCHEMBL3601715 | 0.77 | MAPT (0.65) | CYP1A2CYP2D6MAPTKMT2ARAF1 | |
| SCHEMBL3598467 | 0.77 | MAPT (0.60) | CYP1A2CYP2D6MAPTKMT2ARAF1 | |
| SCHEMBL28025178 | 0.77 | CYP1A2 (0.56) | CYP1A2CYP2D6MAPTKMT2ARAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | BAKER STEWART JAMES | 2010-10-07 | — | — | US | disclosed |
| EP-2146981-A1 | PHARMACEUTICAL COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008125833-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, JAK2 | CYP1A2 1185/4885CYP2D6 1107/4885MAPT 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.